Efficacy of High-Ozonide Oil in Prevention of Cancer Relapses Mechanisms and Clinical Evidence.
cancer prevention
cancer therapy
oxidation
ozonized oil
prevention of cancer relapses
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
24 Feb 2022
24 Feb 2022
Historique:
received:
12
01
2022
revised:
11
02
2022
accepted:
22
02
2022
entrez:
10
3
2022
pubmed:
11
3
2022
medline:
11
3
2022
Statut:
epublish
Résumé
Cancer tissue is characterized by low oxygen availability triggering neo angiogenesis and metastatisation. Accordingly, oxidation is a possible strategy for counteracting cancer progression and relapses. Previous studies used ozone gas, administered by invasive methods, both in experimental animals and clinical studies, transiently decreasing cancer growth. This study evaluated the effect of ozonized oils (administered either topically or orally) on cancer, exploring triggered molecular mechanisms. In vitro, in lung and glioblastoma cancer cells, ozonized oils having a high ozonide content suppressed cancer cell viability by triggering mitochondrial damage, intracellular calcium release, and apoptosis. In vivo, a total of 115 cancer patients (age 58 ± 14 years; 44 males, 71 females) were treated with ozonized oil as complementary therapy in addition to standard chemo/radio therapeutic regimens for up to 4 years. Cancer diagnoses were brain glioblastoma, pancreas adenocarcinoma, skin epithelioma, lung cancer (small and non-small cell lung cancer), colon adenocarcinoma, breast cancer, prostate adenocarcinoma. Survival rate was significantly improved in cancer patients receiving HOO as integrative therapy as compared with those receiving standard treatment only. These results indicate that ozonized oils at high ozonide may represent an innovation in complementary cancer therapy worthy of further clinical studies.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer tissue is characterized by low oxygen availability triggering neo angiogenesis and metastatisation. Accordingly, oxidation is a possible strategy for counteracting cancer progression and relapses. Previous studies used ozone gas, administered by invasive methods, both in experimental animals and clinical studies, transiently decreasing cancer growth. This study evaluated the effect of ozonized oils (administered either topically or orally) on cancer, exploring triggered molecular mechanisms.
METHODS
METHODS
In vitro, in lung and glioblastoma cancer cells, ozonized oils having a high ozonide content suppressed cancer cell viability by triggering mitochondrial damage, intracellular calcium release, and apoptosis. In vivo, a total of 115 cancer patients (age 58 ± 14 years; 44 males, 71 females) were treated with ozonized oil as complementary therapy in addition to standard chemo/radio therapeutic regimens for up to 4 years.
RESULTS
RESULTS
Cancer diagnoses were brain glioblastoma, pancreas adenocarcinoma, skin epithelioma, lung cancer (small and non-small cell lung cancer), colon adenocarcinoma, breast cancer, prostate adenocarcinoma. Survival rate was significantly improved in cancer patients receiving HOO as integrative therapy as compared with those receiving standard treatment only.
CONCLUSIONS
CONCLUSIONS
These results indicate that ozonized oils at high ozonide may represent an innovation in complementary cancer therapy worthy of further clinical studies.
Identifiants
pubmed: 35267482
pii: cancers14051174
doi: 10.3390/cancers14051174
pmc: PMC8909345
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Oncotarget. 2016 Oct 25;7(43):70715-70737
pubmed: 27683112
Cancer Res. 2017 Sep 15;77(18):4797-4808
pubmed: 28655791
Clin Lab. 2013;59(9-10):1091-7
pubmed: 24273932
Adv Cancer Res. 2014;122:1-67
pubmed: 24974178
Exp Mol Med. 2020 Feb;52(2):192-203
pubmed: 32060354
Free Radic Biol Med. 2017 Jan;102:67-76
pubmed: 27838437
J Pers Med. 2021 Mar 22;11(3):
pubmed: 33809879
Diagnostics (Basel). 2021 Feb 10;11(2):
pubmed: 33578944
Oxid Med Cell Longev. 2015;2015:294303
pubmed: 26273420
J Comput Chem. 2009 Jul 30;30(10):1545-614
pubmed: 19444816
Sci Rep. 2018 Sep 13;8(1):13762
pubmed: 30213983
Int J Mol Sci. 2019 Sep 11;20(18):
pubmed: 31514389
Molecules. 2021 May 21;26(11):
pubmed: 34063952
Cancers (Basel). 2021 Dec 23;14(1):
pubmed: 35008216
Redox Biol. 2013 Jan 18;1:45-9
pubmed: 24024136
Am J Cancer Res. 2017 Jun 01;7(6):1350-1371
pubmed: 28670496
Chem Res Toxicol. 2011 Aug 15;24(8):1231-41
pubmed: 21728338
Carcinogenesis. 2015 Mar;36(3):368-77
pubmed: 25653234
Cancer Cell. 2003 Apr;3(4):347-61
pubmed: 12726861
J Oral Pathol Med. 2012 Oct;41(9):649-61
pubmed: 22494322
Anticancer Res. 2017 Feb;37(2):425-435
pubmed: 28179287
Int J Mol Sci. 2015 Oct 22;16(10):25108-20
pubmed: 26506343
Clin Cancer Res. 2014 Aug 15;20(16):4289-301
pubmed: 24944316
Nat Commun. 2011 Oct 11;2:497
pubmed: 21988913
Cancer Lett. 2015 Jan 28;356(2 Pt A):156-64
pubmed: 24732809
Cells. 2020 Dec 04;9(12):
pubmed: 33291682
Genes Cancer. 2011 Dec;2(12):1117-33
pubmed: 22866203
J Comput Chem. 2014 Oct 15;35(27):1997-2004
pubmed: 25130509